Take two: Is Clovis Oncology a buyout target?

In the absence of an actual biotech buyout to report, speculation will have to do. Bloomberg put the spotlight on Clovis Oncology ($CLVS), which reportedly tried to sell itself a couple of years ago--a mention of which usually causes Clovis CEO Patrick Mahaffy's eyes to start rolling. Why Clovis? Two breakthrough drug designations and a high-profile role in cancer drug development--the industry's sweet spot for deals--didn't hurt its chances. And after AbbVie ($ABBV) agreed to pay a jaw-dropping $21 billion for Pharmacyclics, the sky's the limit in terms of potential premiums. One ambitious analyst at Goldman put a prospective buyout price for the Boulder, CO-based biotech at $179 a share, twice what it's been trading for. Report

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.